Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
Elon Musk Says Tesla Cybercab and Optimus Production Will Start Slowly Before Rapid Growth 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
Rio Tinto Posts Strong Q4 Iron Ore and Copper Output on Operational Recovery 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
LAS VEGAS, April 27, 2017 -- Invuity, Inc. (NASDAQ:IVTY), an advanced surgical illumination company focused on minimal access surgery, today at the 18th American Society of Breast Surgeons annual scientific conference, announced the introduction of PhotonBlade™, a dynamic precision illuminator with enhanced energy delivery.
PhotonBlade represents an entirely new category of Intelligent Photonics®, delivering directed, thermally cool illumination at the precise point of surgical treatment. Further, PhotonBlade’s novel energy platform consists of a proprietary shielded blade for precise cutting and coagulation of tissue, with minimal collateral effect. This sophisticated illumination technology further allows for unique use in a fluid filled environment and does not require a proprietary generator, thereby leveraging widely available operating room equipment and avoiding an institutional capital investment.
"We are very proud and excited with the introduction of PhotonBlade,” stated Philip Sawyer, President and CEO of Invuity. “We collaborated with some of the top surgeons in the country on its unique design, which was created for more visualization and precision of the surgical field. This continues our strategic intention to create entirely new categories of intelligent photonics. The advanced illumination coupled with state-of-the-art energy delivery positions us solidly in an initially estimated $300 million available market for this technology,” continued Sawyer. “This demonstrates Invuity’s commitment to improving surgical treatment options and positively impacting patient lives.”
Dr. Rache Simmons, Chief of Breast Surgery at New York Presbyterian Weill Cornell Medical Center said, “The high-quality, point-of-treatment illumination of PhotonBlade coupled with precise energy delivery provides me with the optimal tool I need to perform oncologically effective procedures through small, remote incisions. Specifically, the intracavity illumination enables me to precisely tunnel deep within a breast cavity to remove some or all of the breast tissue from an incision that can be hidden. Ultimately, this contributes to improved survivorship for my patients, which after removing the cancer, is my number one priority.”
About Invuity®
Invuity, Inc. is a leading medical technology company focused on developing and marketing advanced surgical devices to improve the ability of physicians to perform minimal access surgery through smaller and hidden incisions. The company's proprietary Intelligent Photonics™ technology delivers enhanced visualization which facilitates surgical precision, efficiency and safety. In addition, the company utilizes comprehensive strategic marketing programs to create stronger institutional partnerships. Clinical applications include women’s health, encompassing breast cancer and breast reconstruction surgery, gynecology and thyroid surgery. Additional applications include procedures for electrophysiology, spine, orthopedic, cardiothoracic, and general surgery. Invuity is headquartered in San Francisco, CA. For more information, visit www.invuity.com.
Forward-Looking Statements
This announcement contains forward-looking statements that involve risks and uncertainties, including statements regarding financial projections for 2017, future product introductions, future sales and marketing initiatives, and market opportunities. Actual results could differ materially from those projected in the forward-looking statements as a result of certain risk factors, including, but not limited to: fluctuations in demand or failure to gain market acceptance for the Company's devices; the Company's ability to demonstrate to and gain approval from hospitals to use the Company's devices; the highly competitive business environment for surgical medical devices; the Company's ability to sell its devices at prices that support its current business strategies; difficulty forecasting future financial performance; protection of the Company's intellectual property; and compliance with necessary regulatory clearances or approvals. The Company undertakes no obligation to update the forward-looking information in this release. More information about potential factors that could affect the Company's business and financial results is included in its filings with the Securities and Exchange Commission, including, without limitation, under the captions: "Management's Discussion and Analysis of Financial Condition and Results of Operations," and "Risk Factors," which are on file with the Securities and Exchange Commission.
CONTACTS: Company Contact: Joe Guido Vice President Commercial Marketing & Business Development Invuity, Inc. 415-655-2103 Investors & Media: Mark Klausner Westwicke Partners 443-213-0501 [email protected]
